This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of topically applied CLS003 in healthy subjects with cutaneous warts.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the plasma concentration versus time curve (AUC) of CLS003
Timeframe: 7 days
Number of participants with adverse events
Timeframe: 7 days
Peak Plasma Concentration (Cmax) of CLS003
Timeframe: 7 days
Time to reach Cmax (Tmax)
Timeframe: 7 days